ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

24.97 +0.38 (+1.55%)

Official Closing Price Updated: 4:15 PM EST, Feb 25, 2026 Add to My Watchlist

Price and Volume

Volume	1,757,824
Open	24.64
Bid (Size)	25.02 (100)
Ask (Size)	26.10 (100)
Prev. Close	24.59
Today's Range	24.30 - 25.10
52wk Range	13.40 - 28.35
Shares Outstanding	162,625,379
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview

Today 16:05 EST

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

February 23, 2026

From Acadia Pharmaceuticals Inc.

Via Business Wire

Performance

YTD	-5.0%	-5.0%
1 Month	-7.0%	-7.0%
3 Month	+2.4%	+2.4%
6 Month	-2.9%	-2.9%
1 Year	+28.2%	+28.2%

More News

Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year ↗

February 23, 2026

Via The Motley Fool

This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50% ↗

February 23, 2026

Via The Motley Fool

ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) Emerges as a Value Stock with Strong Fundamentals ↗

February 06, 2026

Via Chartmill

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth Momentum and Technical Setup ↗

January 16, 2026

Via Chartmill

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

February 04, 2026

From Acadia Pharmaceuticals Inc.

Via Business Wire

ACAD Stock Slumps 8% After Hours On Hurdle To EU Approval For Genetic Disorder Drug ↗

February 02, 2026

Via Stocktwits

Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union

February 02, 2026

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference

January 13, 2026

From Acadia Pharmaceuticals Inc.

Via Business Wire

Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling

December 30, 2025

Via MarketMinute

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth Momentum and Technical Setup for Breakout ↗

December 25, 2025

Via Chartmill

Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026

December 18, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome

December 12, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? ↗

December 03, 2025

Via The Motley Fool

Healthcare Investor Exits $13 Million Stake STAAR Surgical Stake as Alcon Deal Drama Looms ↗

December 03, 2025

Via The Motley Fool

PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? ↗

December 03, 2025

Via The Motley Fool

Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? ↗

December 03, 2025

Via The Motley Fool

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth Momentum and Technical Setup ↗

November 24, 2025

Via Chartmill

Why Dyne Therapeutics Stock Was Crushing it This Week ↗

November 21, 2025

Via The Motley Fool

Acadia Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference

November 20, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

Beyond The Numbers: 6 Analysts Discuss ACADIA Pharmaceuticals Stock ↗

November 06, 2025

Via Benzinga

Acadia (ACAD) Q3 2025 Earnings Call Transcript ↗

November 05, 2025

Via The Motley Fool

Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview

November 05, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

Frequently Asked Questions

Is ACADIA Pharmaceuticals Inc. - Common Stock publicly traded?

Yes, ACADIA Pharmaceuticals Inc. - Common Stock is publicly traded.

What exchange does ACADIA Pharmaceuticals Inc. - Common Stock trade on?

ACADIA Pharmaceuticals Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for ACADIA Pharmaceuticals Inc. - Common Stock?

The ticker symbol for ACADIA Pharmaceuticals Inc. - Common Stock is ACAD on the Nasdaq Stock Market

What is the current price of ACADIA Pharmaceuticals Inc. - Common Stock?

The current price of ACADIA Pharmaceuticals Inc. - Common Stock is 24.97

When was ACADIA Pharmaceuticals Inc. - Common Stock last traded?

The last trade of ACADIA Pharmaceuticals Inc. - Common Stock was at 02/25/26 04:15 PM ET

What is the market capitalization of ACADIA Pharmaceuticals Inc. - Common Stock?

The market capitalization of ACADIA Pharmaceuticals Inc. - Common Stock is 4.06B

How many shares of ACADIA Pharmaceuticals Inc. - Common Stock are outstanding?

ACADIA Pharmaceuticals Inc. - Common Stock has 4B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.